newsfilter
← Latest News
GlobeNewswire·

Immunovant Announces Pricing of $450 Million Common Stock Financing

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an